Drugs / BMS-641988
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00644488 | Jul 2008 → Mar 2009 | prostate cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00326586 | May 2006 → Mar 2009 | prostate cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS641988 | “This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.” NCT00326586 ↗ |
| Known as | AR#2 | “BMS-641988 (AR#2)” NCT00644488 ↗ |
| Action | Inhibit | “AR Antagonist (BMS-641988)” NCT00326586 ↗ |
| Route | Oral | “Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks” NCT00644488 ↗ |
| Target | AR | “AR Antagonist (BMS-641988)” NCT00326586 ↗ |